This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is a Surprise Coming for Exact Sciences (EXAS) This Earnings Season?
by Zacks Equity Research
Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences (EXAS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Precision Oncology business is likely to have continued to aid Exact Sciences' (EXAS) performance in the fourth quarter of 2020 amid the coronavirus-led economic doldrums.
What's in Store for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales. However, coronavirus-led disruption is likely to have hurt sales.
Exact Sciences (EXAS) Posts Solid Preliminary Q4 Testing Revenues
by Zacks Equity Research
Exact Sciences' (EXAS) strength in Screening revenue along with a robust COVID-19 testing arm are likely to have boosted the top line significantly.
Exact Sciences (EXAS) Soars: Stock Adds 9.8% in Session
by Zacks Equity Research
Exact Sciences (EXAS) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Stock Investors: What's the Next Hot Industry?
by Tracey Ryniec
Technology won't always be on top. There's a bunch of budding industries that could prove to be winners over the next 5 years.
Exact Sciences (EXAS) Loses 5.6% Despite Beating Q3 Earnings
by Zacks Equity Research
Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q3 earnings.
Exact Sciences (EXAS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 29.41% and 16.35%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Exact Sciences (EXAS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coronavirus Drives Testing Stocks: Is There Room for More Upside?
by Urmimala Biswas
Given the current testing requirements across the world, the diagnostic testing business for COVID-19 is rapidly evolving.
7 Diagnostic and Genomic Stocks Storming Into October
by Kevin Cook
COVID-19 has created an Apollo Mission status for advanced medical technologies and smart investors are profiting.
Why Is Exact Sciences (EXAS) Down 25.3% Since Last Earnings Report?
by Zacks Equity Research
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Exact Sciences' (EXAS) Q2 Earnings Beat, Margin Declines
by Zacks Equity Research
Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q2 earnings.
Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 6.45% and 17.09%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings?
by Zacks Equity Research
Amid the pandemic situation, GW Pharmaceuticals (GWPH), which controls its own manufacture and supply chain, is expected to have faced minimum supply-related disruption unlike others.
What's in the Cards for CVS Health (CVS) in Q2 Earnings?
by Zacks Equity Research
CVS Health's (CVS) consumer centric digital strategy becomes even more relevant in Q2 with people increasingly using technology while staying at home.
OPKO Health (OPK) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
OPKO Health's (OPK) second-quarter results are likely to reflect solid performance from Products segment and RAYALDEE.
STAAR Surgical (STAA) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
STAAR Surgical's (STAA) ICL line of products is likely to have boosted Q2 performance amid the coronavirus pandemic.
Should You Buy Exact Sciences (EXAS) Ahead of Earnings?
by Zacks Equity Research
Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
STERIS (STE) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS (STE) registers declines in Healthcare Products with neutral performance in Life Science and AST in April, which is likely to have impacted Q1 earnings.
LabCorp (LH) Beats Q2 Earnings Estimates, Margins Decline
by Zacks Equity Research
LabCorp (LH) witnesses a 20.7% decline in organic volume, partially offset by acquisition volume growth of 1.2%.
T2 Biosystems (TTOO) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
T2 Biosystems' (TTOO) second-quarter results are likely to reflect growth in product revenues.
Zimmer Biomet (ZBH) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet's (ZBH) Hips and Knees portfolios are expected to have contributed to second-quarter top line despite pandemic-led business disruptions.